BRCA2 and neoplasm: uLMS are more likely to show HRD than non-uLMS and the proportion of HR-deficient uLMS is among the highest of all tumor types in TCGA (46); uLMS show the highest rate of homozygous BRCA2 deletion in comparative analyses (47); our case report also demonstrates BRCAness in non-uLMS and motivates the possibility of including the option of PARP inhibition in non-uLMS in therapeutic considerations.